Skip to main content

Table 3 Secondary effectiveness outcomes

From: Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis

  ARNI
(N = 87)
Standard treatment
(N = 100)
p-value
Clinical signs and symptoms of HF (%)
 Dyspnea 6 (6.9) 22 (22.0) 0.004
 Orthopnea* 5 (5.8) 16 (16.0) 0.036
 Fatigue* 2 (2.3) 14 (14.0) 0.004
 Edema 40 (46.0) 58 (58.0) 0.101
Changes of HF-specific parameters**
 NT-proBNP (pg/mL) − 466 (2011) − 81 (2341) 0.170
 LVEF (%) + 13.0 (16.0) + 12.0 (16.8) 0.389
  1. LVEF = left ventricular ejection fraction, NT-proBNP = N-terminal pro B-type natriuretic peptide,
  2. *Fisher Exact test
  3. **Reported as median (interquartile range)
  4. ***Changes of NT-proBNP was reported in 57 and 59 patients in ARNI group and standard treatment group, respectively
  5. −Changes of LVEF was reported in 51 and 60 patients in ARNI group and standard treatment group, respectively